Frank Torti
Director; President and Vant Chair · 3 filings · Latest: Apr 7, 2026
Immunovant, Inc.
Roivant Sciences Ltd.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ROIV | Frank Torti | President and Vant Chair | Feb 23, 2026 | Sale | $27.51 | 587,390 | $16.2M | 13,736,547 | |
ROIV | Frank Torti | President and Vant Chair | Feb 23, 2026 | Option Exercise | $3.85 | 587,390 | $2.3M | 14,323,937 | |
ROIV | Frank Torti | President and Vant Chair | Feb 20, 2026 | Sale | $27.15 | 1,012,610 | $27.5M | 13,736,547 | |
ROIV | Frank Torti | President and Vant Chair | Feb 20, 2026 | Option Exercise | $3.85 | 1,012,610 | $3.9M | 14,749,157 | |
ROIV | Frank Torti | President and Vant Chair | Feb 19, 2026 | Sale | $27.42 | 1,400,000 | $38.4M | 13,736,547 | |
ROIV | Frank Torti | President and Vant Chair | Feb 19, 2026 | Option Exercise | $3.85 | 1,400,000 | $5.4M | 15,136,547 | |
ROIV | FRANK TORTI | — | Feb 20, 2026 | Proposed Sale | $27.52 | 1,600,000 | $44.0M | — | |
ROIV | FRANK TORTI | — | Feb 19, 2026 | Proposed Sale | $27.48 | 1,400,000 | $38.5M | — | |
ROIV | FRANK M TORTI | — | Dec 24, 2025 | Proposed Sale | $22.47 | 64,891 | $1.5M | — |